Flurpiridaz-F-18- Nihon Medi-Physics
Alternative Names: flurpiridaz - Nihon Medi-Physics Co; NMB-58Latest Information Update: 11 Apr 2025
At a glance
- Originator Nihon Medi-Physics
- Class Chlorinated hydrocarbons; Ethers; Fluorinated hydrocarbons; Fluorine radioisotopes; Imaging agents; Ketones; Pyridazines; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Ischaemic heart disorders
- No development reported Myocardial infarction
Most Recent Events
- 31 Mar 2025 Nihon Medi-Physics has been acquired by GE Healthcare
- 28 Aug 2023 No recent reports of development identified for phase-I development in Myocardial-infarction(Diagnosis, In volunteers, In adults) in Japan (IV)
- 05 Jan 2022 Efficacy data from a phase I trial in myocardial perfusion imaging released Nihon Medi-Physics